[Immunoscintigraphy with emission tomography in cancers of the thyroid].
Immunoscintigraphy (IS) consists of in vivo body structure imaging using a specific labelled antibody to an antigen concentrated in the structure under study. Technically, the image contrast is better when IS is performed with a computerized emission tomography system. High concentrations of carcinoembryonic antigen (CEA) have been reported in medullary thyroid carcinoma and thyroglobulin (Tg) is a marker for differentiated thyroid carcinoma. We used injections of 131-I labelled monoclonal antibodies to CEA and Tg to detect thyroid tumours. A feasibility trial using anti-CEA antibodies gave very encouraging results. However, only tumours larger than 10 cm3 could be detected. Contradictory results were obtained using anti-Tg antibodies but this data must be considered as preliminary. Various means of improving the method and the concept of accessibility of the antigen to the antibody in vivo are discussed. This study shows IS to be a promising experimental technique. Further studies are required to define its clinical indications before it can be advocated for routine use.
D000818:Animals; D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen / Q000276:immunology; D002277:Carcinoma / Q000000981:diagnostic imaging*; D006801:Humans; D051379:Mice; D051381:Rats; D013954:Thyroglobulin / Q000276:immunology; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed
D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D013954:Thyroglobulin
Immunoscintigraphie avec tomographie d'émission dans les cancers de la thyroïde.